Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
MCA, Sebi plan investor camps for faster transfer of unclaimed shares, dividends
19/04/2025
Investors should cut US positions, favour Europe, China, India : Wood
19/04/2025
Margin Call : Banks cut rates to boost profits
19/04/2025
Beijing to help tariff-hit exporters find local buyers
18/04/2025
PhonePe converts to public company ahead of planned IPO
18/04/2025
Pakistan expels over 80,000 Afghans in push ahead of April 30 deadline, adviser says
18/04/2025
